LC
KNSA icon

Lindbrook Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Lindbrook Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$5.06K Hold
228
– – ﹤0.01% 1946
2024
Q4 		$4.51K Hold
228
– – ﹤0.01% 2030
2024
Q3 		$5.7K Sell
228
-457
-67% -$11.1K ﹤0.01% 1958
2024
Q2 		$12.8K Buy
685
+25
+4% +$468 ﹤0.01% 1491
2024
Q1 		$13K Buy
660
+2
+0.3% +$39 ﹤0.01% 1421
2023
Q4 		$11.5K Buy
658
+49
+8% +$805 ﹤0.01% 1472
2023
Q3 		$10.6K Buy
609
+29
+5% +$489 ﹤0.01% 1385
2023
Q2 		$8.17K Hold
580
– – ﹤0.01% 1589
2023
Q1 		$6.24K Buy
580
+123
+27% +$1.62K ﹤0.01% 1755
2022
Q4 		$6.85K Sell
457
-26
-5% -$379 ﹤0.01% 1639
2022
Q3 		$6K Buy
483
+460
+2,000% +$5.24K ﹤0.01% 1564
2022
Q2 		$0 Buy
+23
New +$215 ﹤0.01% 2626

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lindbrook Capital's KNSA Position: Q1 2025 in Review

Lindbrook Capital held its Kiniksa Pharmaceuticals (KNSA) position steady in Q1 2025 at 228 shares worth $5.06K. The position accounts for ﹤0.01% of the portfolio, ranked #1946.

Lindbrook Capital first reported a position in KNSA in Q2 2022 and has held it in 12 quarters since. The position peaked at $13K in Q1 2024. 176 funds tracked by Wall St. Rank hold KNSA as of Q1 2025.

  • Lindbrook Capital held 228 shares of Kiniksa Pharmaceuticals worth $5.06K as of Q1 2025.
  • Lindbrook Capital left its Kiniksa Pharmaceuticals share count unchanged in Q1 2025.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1946 holding.
  • Lindbrook Capital first reported a position in Kiniksa Pharmaceuticals in Q2 2022 and has held it in 12 quarters since.
  • Lindbrook Capital's Kiniksa Pharmaceuticals position peaked at $13K in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.